Multiple Sclerosis (MS)
Original Editors -Sarah Demarest & Beth Niehbur from Bellarmine University's Pathophysiology of Complex Patient Problems project.
Top Contributors - Elizabeth Niebuhr, Vidya Acharya, Sarah Demarest, Laura Ritchie, Nikhil Benhur Abburi, Garima Gedamkar, Kim Jackson, Bram Van Laer, Lucinda hampton, Admin, Eta Frida, Rachael Lowe, Magdalena Hytros, WikiSysop, Naomi O'Reilly, 127.0.0.1, Elaine Lonnemann, Wendy Walker, Evan Thomas, Memoona Awan, Venus Pagare, Sheik Abdul Khadir, Elien Lebuf, Tarina van der Stockt, Rucha Gadgil, Jaroslaw Pospiech, Jess Bell and Rishika Babburu </div>
Definition/Description[edit | edit source]
Multiple Sclerosis (MS) is an autoimmune disorder in which the body's immune cells attack the central nervous system (CNS), affecting the brain, spinal cord and optic nerve[1]. MS is characterized by inflammation, demyelination and gliosis[2]. An inflammatory response occurs when the body's immune cells attack the CNS, which leads to an increase in pressure and therefore disrupting the nerve conductivity. Demyelination is a process where a nerves protective covering, known as myelin, is damaged due to the autoimmune response leading to decreased nerve conduction velocity and early fatigue of the nerve. Gliosis occurs when demyelinated areas become fibrotic, which causes proliferation of neuroglial tissue in the CNS and leads to scarring of the tissue[2].
The course that MS can take will be different from one person to another as well as unpredictable. The disease can be divided into four clinical subytpes, which describe how the disease will progress as well as the corresponding characteristics that become evident for each subtype. Relapsing-remitting MS (RRMS) is the most commone subtype, affecting 85% of people with MS and is characterized by short attacks to the CNS followed by complete or partial return to normal functioning[2]. Secondary-progressive MS (SPMS) is a subgroup that begins as a relapsing-remitting course accompanied by a steady decline in function and is often developed by patient. Primary-Progressive MS (PPMS) is a progression of the disease where a steady decline in function experienced from the onset of the disease. Progressive-Relapsing MS (PRMS) is similar to PPMS but has the additional characteristic of acute attacks.
Prevalence[edit | edit source]
It is estimated that in the United States there are 400,000 people ebing affected by MS and 2.1 million globally.
Characteristics/Clinical Presentation[edit | edit source]
add text here
Associated Co-morbidities[edit | edit source]
add text here
Medications[edit | edit source]
add text here
Diagnostic Tests/Lab Tests/Lab Values[edit | edit source]
add text here
Etiology/Causes[edit | edit source]
add text here
Systemic Involvement[edit | edit source]
add text here
Medical Management (current best evidence)[edit | edit source]
add text here
Physical Therapy Management (current best evidence)[edit | edit source]
add text here
Alternative/Holistic Management (current best evidence)[edit | edit source]
add text here
Differential Diagnosis[edit | edit source]
add text here
Case Reports/ Case Studies[edit | edit source]
add links to case studies here (case studies should be added on new pages using the case study template)
Resources
[edit | edit source]
add appropriate resources here
Recent Related Research (from Pubmed)[edit | edit source]
see tutorial on Adding PubMed Feed
Extension:RSS -- Error: Not a valid URL: addfeedhere|charset=UTF-8|short|max=10
References[edit | edit source]
- ↑ 1.0 1.1 U.S National Library of Medicine. PubMed Health. Multiple Sclerosis. September 25, 2013. Available at:http: //www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/,Accessed March 19, 2014.
- ↑ 2.0 2.1 2.2 O'Sullivan S, Schmitz T, Fulk G: Physical Rehabilitation. 6th edition. Philadelphia, PA. F.A. Davis Company; 2014.
see adding references tutorial.
